Perspectives of bilateral thoracic sympathectomy for treatment of heart failure
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/213037 |
Resumo: | Surgical neuromodulation therapies are still considered a last resort when standard therapies have failed for patients with progressive heart failure (HF). Although a number of experimental studies have provided robust evidence of its effectiveness, the lack of strong clinical evidence discourages practitioners. Thoracic unilateral sympathectomy has been extensively studied and has failed to show significant clinical improvement in HF patients. Most recently, bilateral sympathectomy effect was associated with a high degree of success in HF models, opening the perspective to be investigated in randomized controlled clinical trials. In addition, a series of clinical trials showed that bilateral sympathectomy was associated with a decreased risk of sudden death, which is an important outcome in patients with HF. These aspects indicates that bilateral sympathectomy could be an important alternative in the treatment of HF wherein pharmacological treatment barely reaches the target dose. |
id |
USP-19_bc9bc842579069624d1567f553fe4a5d |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/213037 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Perspectives of bilateral thoracic sympathectomy for treatment of heart failureHeart FailureSympathectomyMyocardial InfarctionDilated CardiomyopathyPulmonary HypertensionSurgical neuromodulation therapies are still considered a last resort when standard therapies have failed for patients with progressive heart failure (HF). Although a number of experimental studies have provided robust evidence of its effectiveness, the lack of strong clinical evidence discourages practitioners. Thoracic unilateral sympathectomy has been extensively studied and has failed to show significant clinical improvement in HF patients. Most recently, bilateral sympathectomy effect was associated with a high degree of success in HF models, opening the perspective to be investigated in randomized controlled clinical trials. In addition, a series of clinical trials showed that bilateral sympathectomy was associated with a decreased risk of sudden death, which is an important outcome in patients with HF. These aspects indicates that bilateral sympathectomy could be an important alternative in the treatment of HF wherein pharmacological treatment barely reaches the target dose.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2021-08-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/21303710.6061/clinics/2021/e3248Clinics; Vol. 76 (2021); e3248Clinics; v. 76 (2021); e3248Clinics; Vol. 76 (2021); e32481980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/213037/195043Copyright (c) 2023 Clinicsinfo:eu-repo/semantics/openAccessCoutinho e Silva, Raphael dos SantosZanoni, Fernando LuizSimas, RafaelMoreira, Luiz Felipe Pinho2023-07-06T13:04:10Zoai:revistas.usp.br:article/213037Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2023-07-06T13:04:10Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Perspectives of bilateral thoracic sympathectomy for treatment of heart failure |
title |
Perspectives of bilateral thoracic sympathectomy for treatment of heart failure |
spellingShingle |
Perspectives of bilateral thoracic sympathectomy for treatment of heart failure Coutinho e Silva, Raphael dos Santos Heart Failure Sympathectomy Myocardial Infarction Dilated Cardiomyopathy Pulmonary Hypertension |
title_short |
Perspectives of bilateral thoracic sympathectomy for treatment of heart failure |
title_full |
Perspectives of bilateral thoracic sympathectomy for treatment of heart failure |
title_fullStr |
Perspectives of bilateral thoracic sympathectomy for treatment of heart failure |
title_full_unstemmed |
Perspectives of bilateral thoracic sympathectomy for treatment of heart failure |
title_sort |
Perspectives of bilateral thoracic sympathectomy for treatment of heart failure |
author |
Coutinho e Silva, Raphael dos Santos |
author_facet |
Coutinho e Silva, Raphael dos Santos Zanoni, Fernando Luiz Simas, Rafael Moreira, Luiz Felipe Pinho |
author_role |
author |
author2 |
Zanoni, Fernando Luiz Simas, Rafael Moreira, Luiz Felipe Pinho |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Coutinho e Silva, Raphael dos Santos Zanoni, Fernando Luiz Simas, Rafael Moreira, Luiz Felipe Pinho |
dc.subject.por.fl_str_mv |
Heart Failure Sympathectomy Myocardial Infarction Dilated Cardiomyopathy Pulmonary Hypertension |
topic |
Heart Failure Sympathectomy Myocardial Infarction Dilated Cardiomyopathy Pulmonary Hypertension |
description |
Surgical neuromodulation therapies are still considered a last resort when standard therapies have failed for patients with progressive heart failure (HF). Although a number of experimental studies have provided robust evidence of its effectiveness, the lack of strong clinical evidence discourages practitioners. Thoracic unilateral sympathectomy has been extensively studied and has failed to show significant clinical improvement in HF patients. Most recently, bilateral sympathectomy effect was associated with a high degree of success in HF models, opening the perspective to be investigated in randomized controlled clinical trials. In addition, a series of clinical trials showed that bilateral sympathectomy was associated with a decreased risk of sudden death, which is an important outcome in patients with HF. These aspects indicates that bilateral sympathectomy could be an important alternative in the treatment of HF wherein pharmacological treatment barely reaches the target dose. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-08-04 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/213037 10.6061/clinics/2021/e3248 |
url |
https://www.revistas.usp.br/clinics/article/view/213037 |
identifier_str_mv |
10.6061/clinics/2021/e3248 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/213037/195043 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2023 Clinics info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2023 Clinics |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 76 (2021); e3248 Clinics; v. 76 (2021); e3248 Clinics; Vol. 76 (2021); e3248 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222766246395904 |